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Abstract  47 
 48 
Background: South Africa is among the 7 highest tuberculosis (TB) burden countries. 49 
Harmful lifestyle behaviours, such as smoking and alcohol, and poor medication adherence 50 
can affect clinical outcomes. Modification of these behaviours is likely to improve TB 51 
treatment outcomes and has proven possible using motivational interviewing (MI) techniques 52 
or use of short message service (SMS) text messaging. There have been no studies assessing 53 
the effect of combined MI and SMS interventions on multiple lifestyle factors and TB 54 
treatment outcomes. 55 
 56 
Methods: This is a prospective, multi-centre, two-arm individual randomised controlled trial 57 
looking at the effectiveness and cost-effectiveness of a complex behavioural intervention (the 58 
ProLife programme) on improving TB and lifestyle-related outcomes in 3 provinces of South 59 
Africa. The ProLife programme consists of an MI counselling strategy, delivered by lay 60 
health workers, augmented with subsequent SMS. We aim to recruit 696 adult participants 61 
(aged 18 years and over) with drug-sensitive pulmonary TB who are current smokers and/or 62 
report harmful or hazardous alcohol use. Patients will be consecutively enrolled at 27 clinics 63 
in 3 different health districts in South Africa. Participants randomised individually to the 64 
intervention arm will receive 3 MI counselling sessions 1 month apart. Each MI session will 65 
be followed by twice-weekly SMS messages targeting treatment adherence, alcohol use and 66 
tobacco smoking, as appropriate. We will assess the effect on TB treatment success, using 67 
standard World Health Organization (WHO) treatment outcome definitions (primary 68 
outcome), as well as on a range of secondary outcomes including smoking cessation, 69 
reduction in alcohol use and TB medication and anti-retroviral therapy adherence. Secondary 70 
outcomes will be measured at 3 and 6 months follow-up. 71 
 72 
Discussion: This trial aligns with the WHO agenda of integrating TB care with the care for 73 
chronic diseases of life-style, such as provision of smoking cessation treatments, and with the 74 
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use of digital technologies. If the ProLife programme is found to be effective and cost-75 
effective, the programme could have significant implications for TB treatment globally and 76 
could be successfully implemented in a wide range of TB treatment settings.  77 
 78 
Trial registration: ISRCTN62728852, Registered on 13th April 2018  79 
 80 
Key words: Tuberculosis, smoking, alcohol, motivational interviewing, anti-retroviral 81 
therapy, adherence  82 
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Background 83 
South Africa has the second highest incidence of tuberculosis (TB) and the sixth highest TB 84 
burden of the 30 high TB burden countries. It also has a high prevalence of human 85 
immunodeficiency virus (HIV) co-infection in patients with TB and a high mortality in these 86 
co-infected patients relative to most other high-burden countries [1]. In addition to HIV co-87 
infection, a range of social, psychological and economic factors influence treatment success 88 
in TB. Of these, tobacco smoking and hazardous or harmful alcohol use are specifically 89 
mentioned in the South Africa National TB Management Guidelines [2]. Tobacco use and 90 
problem drinking are prevalent in TB patients, often co-occur [3,4,5] and are known to 91 
increase the risk of death and poor treatment adherence and outcomes [6,7,8,9].  92 
 93 
As well as increasing the risk of TB infection and progression of disease [10], smoking is also 94 
known to increase the risk of treatment failure [11], relapse [12,13] and death [14], and is 95 
associated with resistance to isoniazid, one of the main antimicrobials used to treat TB [15]. 96 
There is evidence that patients who stop smoking have better TB treatment outcomes and, if 97 
co-infected, better HIV treatment outcomes than current smokers [16,17,18]. In addition, 98 
alcohol misuse is associated with poorer TB outcomes through a range of mechanisms 99 
including decreased effectiveness of medications used to treat TB (including drug resistance), 100 
increased recurrence and treatment default rates and social marginalisation [19]. It has been 101 
estimated that 10% of the global burden of TB is attributable to alcohol use [20]. 102 
 103 
Poor adherence to TB medication and anti-retroviral therapy (ART) significantly increases 104 
the risk of adverse effects and death in TB patients. Strategies are needed to improve 105 
medication adherence in TB-HIV co-infected patients, in whom integration of TB and HIV 106 
care has been shown to decrease mortality [1]. 107 
 108 
A number of studies have attempted to evaluate the effectiveness of tobacco cessation, 109 
alcohol reduction or TB treatment adherence interventions in TB patients [22,23], but few  110 
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have assessed the effect on TB treatment outcomes [24,25]. We know that brief smoking 111 
cessation interventions, ranging from opportunistic advice and proactive telephone support 112 
through to in-person behavioural support over multiple sessions, are effective and affordable 113 
in low-income countries, in both TB patients and smokers in the general population [26,27]. 114 
We also know that disease diagnosis could constitute DµWHDFKDEOHPRPHQW¶ZKHQSHRSOHDUH115 
more amenable to advice and motivated to modify harmful lifestyle behaviours [28]. For this 116 
reason, it is likely that patients receiving a TB diagnosis may be more successful in quitting 117 
smoking and moderating alcohol use if offered behavioural support, compared with smokers 118 
and problem drinkers in the general population.  119 
 120 
Motivational interviewing (MI) is a counselling technique known to facilitate behaviour 121 
change [29], which has demonstrated effectiveness for the reduction of hazardous drinking, 122 
tobacco cessation and TB treatment and/or ART adherence [20,30,31]. Our group has had 123 
previous success in achieving sustained smoking abstinence in TB patients through a brief MI 124 
intervention delivered by lay health workers (LHWs) [32]. There is also evidence to suggest 125 
that adherence to ART [33] and possibly TB medication [34], as well as tobacco cessation can 126 
be enhanced with the use of short message service (SMS) text messages on mobile phone 127 
technology [35]. To our knowledge, no study has used MI in combination with SMS text 128 
messages to address multiple harmful behaviours that adversely impact TB outcomes.  129 
 130 
The ProLife programme is a novel complex behavioural intervention targeting tobacco 131 
smoking, problem drinking and TB and HIV medication adherence in patients with TB. This 132 
is the study protocol for the randomised controlled trial (RCT) aiming to assess the 133 
effectiveness and cost-effectiveness of the ProLife programme in improving TB treatment 134 
outcomes in primary health care clinics located in high TB-burden communities in 3 135 
provinces in South Africa (Gauteng, Free state and North West). The protocol has been 136 
written in accordance with the Standard Protocol Items: Recommendations for Intervention 137 
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Trials (SPIRIT) guideline. 138 
 139 
Methods/Design 140 
Objectives 141 
The primary objective is to assess the effectiveness and cost-effectiveness of the ProLife 142 
programme compared to usual care in improving pulmonary TB (PTB) treatment outcomes. 143 
We also aim to assess the effectiveness and cost-effectiveness of the programme in achieving 144 
abstinence from smoking, reducing harmful and hazardous drinking and improving TB and 145 
ART medication adherence.  146 
 147 
Trial design and setting 148 
This is a pragmatic, prospective, multi-centre, two-arm, parallel, individual RCT taking place 149 
in 27 purposively selected primary care clinics with the highest TB case-load in 3 districts in 150 
South Africa: Welkom in the Free State, Bojanala in the North West province and Sedibeng 151 
in Gauteng province. To be eligible for inclusion in the trial, TB clinics had to be under the 152 
control of the provincial or local government (i.e. not a mining TB clinic). The intervention 153 
will be delivered by LHWs and 3 district coordinators who will each cover 1-2 clinics.  154 
Participants will be randomly allocated to one of two arms: 155 
Arm 1: Intervention arm ± Participants in the interventions arm will receive the ProLife 156 
programme. 157 
Arm 2: Control arm ± Participants will receive usual treatment and support provided to TB 158 
SDWLHQWVLQ7%WUHDWPHQWFOLQLFVLQ6RXWK$IULFD³XVXDOFDUH´ 159 
 160 
Intervention 161 
The ProLife programme is a complex behavioural intervention aimed at improving treatment 162 
outcomes in TB patients who smoke tobacco, drink alcohol at harmful or hazardous levels or 163 
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do both. The ProLife programme has been developed in line with the Medical Research 164 
Council (MRC) guidance on developing and evaluating complex interventions [36] and has 165 
undergone a period of development and feasibility testing in South Africa. The paper 166 
reporting the results of this evaluation has not yet been published. The conceptual framework 167 
used to develop the ProLife programme assumes that smoking cessation, reducing harmful 168 
alcohol use and improved adherence to TB and HIV treatment will result in improved TB 169 
treatment outcomes. 170 
 171 
Participants randomised to the intervention arm will receive 3 brief MI counselling sessions, 172 
lasting 15-20 minutes, each 1 month apart, from a trained LHW at their TB clinic. In the 173 
initial MI session, occurring at the start of TB treatment, the counsellor will establish the 174 
SDUWLFLSDQW¶V WREDFFR VPRNLQJ KDELWV SUREOHP GULQNLQJ DQG SRWHQWLDO REVWDFOHV DQG175 
facilitators for medication adherence or treatment initiation (both TB treatment and ART) will 176 
be determined. The participant will determine which factor should be prioritised (i.e. agenda 177 
setting), which could be a plan either to quit tobacco smoking, reduce or quit drinking or deal 178 
with barriers relating to ART or TB medication adherence. For participants who are HIV-179 
infected and not yet on ART, beliefs and attitudes regarding HIV-testing or ART will be 180 
explored to facilitate ART initiation and adherence. The second session will build on the 181 
previous one and will focus on the previous agenda before moving on to the next behavioural 182 
problem (tobacco, alcohol or medication adherence) where applicable. The third session will 183 
deal with the last identified problem.  184 
 185 
The individual counselling sessions will be re-enforced with SMS text messages  regarding 186 
information, motivation and behaviours (IMB) supporting tobacco cessation, alcohol use and 187 
medication adherence. Text messages will be delivered twice a week over 12 weeks. All 188 
participants will first receive 10 TB-related messages. These messages will be followed by 7 189 
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alcohol or smoking-related messages depending on whether the participant smokes or drinks. 190 
Co-joint users will receive all sets of messages (i.e. 24 in total). 191 
 192 
Comparator 193 
Participants in the second group are the control and will receive usual TB treatment and 194 
support offered to TB patients. Control participants are seen by a TB nurse and receive the 195 
same biochemical investigations and medical treatments as the intervention arm. However, 196 
they will not receive the MI and SMS package of care as described above. Usual care also 197 
includes HIV testing with pre-and post-test HIV test counselling by a lay counsellor or a 198 
nurse (this varies by district).  199 
In addition, health education is given on:  200 
Nature of TB, treatment adherence, treatment side-effects/complications, drug interactions, 201 
tobacco use, alcohol use and other substance abuse. This is mostly done by the TB nurses, is 202 
not intensive and is educational in nature rather than a form of counselling. 203 
+HDOWK\GLHWE\DGietician where possible. 204 
6RFLDOSUREOHPVDnd family support for treatment by a social worker as needed and 205 
depending on the availability of social workers. 206 
3RLQWRIFDUHEORRGJOXFRVHKDHPRJORELQDQGSUHJQDQF\WHVWs are done. If co-infected with 207 
HIV, a full blood count, liver function test and creatinine are also done. 208 
 209 
Participants 210 
The inclusion criteria for participants are: 211 
Ɣ Adult patients (18 years or older) with drug-sensitive (bacteriologically or clinically 212 
confirmed) pulmonary TB, 213 
Ɣ Initiating TB treatment or on TB treatment for less than a month (these include both 214 
³QHZ´DQG³UHWUHDWPHQWSDWLHQWV´, 215 
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Ɣ Current smokers and/or hazardous/harmful drinkers who are not alcohol dependent 216 
(Alcohol Use Disorders Identification Test (AUDIT) VFRUHIRUPHQRUIRU217 
women but <20), 218 
Ɣ Access to a functional mobile phone, and 219 
Ɣ Understands one of the 4 languages used for the trial (Sesotho, Setswana, Isizulu or 220 
English) 221 
 222 
Exclusion criteria: 223 
Ɣ Alcohol dependent participants (AUDIT score more than or equal to 20),  224 
Ɣ Extrapulmonary tuberculosis without pulmonary TB, or 225 
Ɣ Resistance to one or more TB drugs at baseline (because drug-resistant TB needs 226 
further investigations which take several months and is treated through a long 227 
specialised treatment programme if present).  228 
 229 
Recruitment process 230 
Participants will be recruited consecutively from the starting date of the trial until the required 231 
sample size for each clinic has been achieved. The sample size per clinic will vary depending 232 
on the workload for each clinic. TB patients who initiate treatment (or who have been on 233 
treatment for less than 1 month) will be asked if they would like to participate. If they agree, 234 
they will then be screened for eligibility by trained fieldworkers immediately after the TB 235 
nurse at the clinic has initiated TB treatment and started the routinely-used TB treatment 236 
record. Eligibility screening will involve being assessed in line with the inclusion criteria 237 
listed above and being asked about their:  238 
Ɣ Smoking status: using Global Adult Tobacco Survey [37] questionnaire, patients will 239 
be asked whether they currently smoke daily, less than daily, or not at all and in the 240 
past daily, less than daily or not at all. As TB patients in South Africa often smoke 241 
little or may not have smoked for a few days because of ill-health and the word 242 
³FXUUHQW´ LV RSHQ WR LQWHUSUHWDWLRQ LQ SDUWLFXODUO\ ZKHQ WUDQVODWHG ³FXUUHQW´ KDV243 
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been defined as smoking daily and non-daily in the last four weeks for the purpose of 244 
this study. Smoking habits will be further quantified at baseline interview.  245 
Ɣ Current alcohol usage: using AUDIT, a validated tool for identifying problem alcohol 246 
behaviours [38]ZLOOEHXVHGWRTXDQWLI\DOFRKROLQWDNH7KRVHZLWK$8',7VFRUH247 
IRUPHQRUIRUZRPHQEXWZLOOEHHOLJLEOHIRUWKHWULDO 248 
 249 
If eligible, patients will be invited to join the trial. For those who wish to be enrolled into the 250 
trial, written informed consent will be obtained (Appendix 1).  251 
 252 
Randomisation and allocation 253 
Patients will be randomised using a randomised sequence generator performed by the trial 254 
statistician (MK), who will remain blind to the arm allocation. We will use block 255 
randomisation with varying block sizes stratified by clinic so as to achieve equal numbers in 256 
intervention and control groups within each clinic (see Sample Size section). Allocation 257 
concealment will be done with consecutively numbered, sealed, opaque envelopes.  258 
 259 
Ethics and consent 260 
Potential participants will be approached and given an introduction to the study and basic 261 
eligibility criteria required for participation.  Participants who meet the eligibility criteria for 262 
language, age, pulmonary TB, treatment duration, and mobile phone access will be given a 263 
consent form (Appendix 1) to sign prior to alcohol and tobacco use eligibility screening as the 264 
alcohol related questions are sensitive and the fieldworkers must access the patient treatment 265 
record. If recruited to the trial, participants will be ask to consent to enter the trial, including 266 
consent for audio recording of the MI counselling sessions (Appendix 1). A witness signature 267 
will be required where the participant is unable to read or write.  268 
The identity of participants will be protected by allocating each participant a unique trial 269 
number, which will be used on all research documents and will ensure anonymity for the data 270 
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analysis. Participation will be voluntary and participants will be informed of their right to 271 
withdraw from the study at any time without giving a reason for their withdrawal. The project 272 
is unlikely to be directly harmful to TB patients with the exception of inconvenience in terms 273 
of time spent on the counseling sessions. Participants will receive ZAR 60 (4.19US$) travel 274 
and other expenses reimbursement for each MI counselling session and follow-up visit related 275 
to the study. 276 
 277 
Timeline and procedures 278 
Figure 1 outlines the overall participant flow through the trial. Eligible and consenting 279 
patients will be enrolled in the trial and the baseline interviewer-administered questionnaire 280 
and record review completed. Participants will receive a baseline interview on the same day 281 
as the recruitment or on the nearest available date suitable to both the participant and the 282 
LHW. The initial part of the questionnaire covers socioeconomic and demographic factors. 283 
We will also assess for depression using the CES-D10 [39], a validated tool, as depression 284 
may be a potentially moderating or mediating factor affecting treatment outcome. See 285 
Appendix 2 for the full case report form (CRF). 286 
The next part will cover medical history, particularly TB and HIV history and current 287 
medications. Participants identified as current smokers at eligibility screening will be asked 288 
more in-depth about their smoking habits and quit history. All participants will be asked 289 
about their use of smokeless tobacco and exposure to second-hand smoke. Participants will 290 
also be asked about time and money spent on TB-related health care visits in the past 3 291 
months and health-related quality of life (see economic evaluation section). After 292 
administering the baseline interviews, fieldworkers will draw the allocation envelopes and 293 
organise the follow-up sessions for the participants. Each of the interviews on health status, 294 
tobacco and alcohol use at baseline, 3 months and 6 months is not expected to last more than 295 
25 minutes.  296 
 297 
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Figure 1: CONSORT Flow diagram outlining randomisation and participant recruitment 298 
 299 
Primary outcome 300 
The primary outcome is TB treatment success at 6 to 9 months follow-up, measured using the 301 
routinely collected programmatic TB treatment outcomes as defined by the World Health 302 
Organisation (WHO) and adopted in South Africa. This is a binary variable defined as either 303 
successful treatment (cured or treatment completed) or failed treatment, death, acquired drug 304 
resistance, loss to follow-XSRU³GHIDXOW´RUQRWoutcome evaluated. Table 1 defines the 305 
different treatment outcomes according to the South African Department of Health National 306 
Tuberculosis Management Guidelines [2]. 307 
 308 
Table 1: Definitions for TB treatment outcomes according to the South African Department of 309 
Health National Tuberculosis Management Guidelines 2014 310 
 311 
Individual TB treatment records will be used as the primary source of information. The TB 312 
treatment record is the routinely-used clinical document initiated by the TB nurse when the 313 
patient first presents at the TB clinic and includes demographic information as well as a 314 
FRPSUHKHQVLYHRYHUYLHZRIWKHSDWLHQW¶VWUHDWPHQWRYHUWLPHThe TB treatment outcomes 315 
will be obtained 6-9 months after the TB treatment start dates. This is to allow for short 316 
periods of treatment interruption and time needed to confirm the TB treatment outcomes 317 
status. For example, the TB nurse may have to wait for end of treatment TB sputum or culture 318 
results or time may be required to determine whether a participant died. In some cases TB 319 
patients may also undergo a longer TB treatment regimen.  320 
Routinely reported outcomes will be verified for correctness by checking the actual individual 321 
diagnosis and treatment records. For example: if the outcome is classified as cured, then the 322 
criteria for diagnosis and outcome definitions should have been adhered to. Attempts will be 323 
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PDGHWRYHULI\WKHLQIRUPDWLRQRISDWLHQWVFODVVLILHGDV³GHIDXOWed´RUZKRDUHORVWWRIROORZ-324 
up by contacting them telephonically or sending them a short text message. Sputum cultures 325 
and smears will be performed at baseline, 2 months, 3 months and 6 months per routine care.  326 
 327 
Secondary outcomes 328 
The following outcome measures will also be recorded at 6 month follow-up: 329 
Ɣ Sputum conversion at the end of treatment: This will be measured by negative culture 330 
or smears in the group of participants who had bacteriology confirmed PTB at 331 
baseline, i.e. cure rates in intervention group vs. control group for participants who 332 
initially had sputum AFB positive, culture positive or GeneXpert positive PTB. 333 
Ɣ 6-month continuous smoking abstinence: The Russell Standard defines continuous 334 
abstinence as a self-report of not smoking more than 5 cigarettes from the start of the 335 
abstinence period (in this case 6 months), supported by a negative biochemical test 336 
(exhaled Carbon Monoxide (CO) < 10 ppm) at final follow-up [40]. For the purpose 337 
of our study, we will however use a more stringent criterion of exhaled CO <7ppm, 338 
based on findings from our previous study that some participants who reported 339 
continued smoking had an exhaled CO <10ppm [41]. This analysis will be performed 340 
on the group of participants who were current tobacco smokers at baseline. 341 
Ɣ Reduction in harmful or hazardous drinking: Alcohol use will be measured using the 342 
AUDIT questionnaire. The questionnaire will be administered at screening (which 343 
will take place on the same day or shortly after the baseline assessment) and again at 344 
3 months and 6 months. Changes in the total AUDIT score will be used to compare 345 
change in drinking behaviour between control and intervention groups. This analysis 346 
will be performed on the group of participants who were harmful or hazardous 347 
drinkers at baseline. 348 
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Ɣ TB and ART medication adherence: adherence to both TB and ART medications will 349 
be measured using a modified version of the AIDS Clinical Trials Group (ACTG) 350 
Adherence Questionnaire. The questionnaire is a validated tool for measuring 351 
adherence specifically to ART and we will use an adapted version to also measure TB 352 
medication adherence [42]. Field workers will administer the baseline part of this 353 
questionnaire as part of the baseline CRF and adherence will be measured at both 3 354 
months and 6 months.  355 
Adherence will be measured using an adherence index calculated by the formula 356 
(using the 4-day recall table): 357 
[Total number of doses taken/Total number of doses prescribed] x 100 358 
For ART patients with at least 95% of adherence will be considered as having 359 
optimal adherence and those with less than 95% will be considered as having low (or 360 
suboptimal) adherence. For TB medication regimen, patients with at least 95% of 361 
adherence will be considered as having optimal adherence and those with less than 362 
95% will be considered as having low (or suboptimal) adherence. 363 
Ɣ Increase in proportion of HIV-positive participants on ART: HIV status will be 364 
recorded in the TB Treatment Record. HIV positive participants will be asked about 365 
ART status at baseline, 3 months and 6 months using standardised questions on the 366 
CRF. 367 
The following outcomes will be measured at 3 months: 368 
Ɣ Biochemically verified 3-month sustained tobacco cessation 369 
Ɣ Reduction in harmful or hazardous drinking 370 
Ɣ TB drug and ART adherence  371 
Ɣ Increase in proportion of HIV-positive participants on ART.  372 
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 373 
The schedule for enrolment, intervention and assessments is presented in Figure 2. Table 2 374 
summarises the methods of data collection and analysis for each of the primary and secondary 375 
outcomes.  376 
Figure 2: SPIRIT Figure outlining data collection throughout trial 377 
 STUDY PERIOD 
 
Enrolment Allocation Post-allocation 
Close-
out 
TIMEPOINT -t 0 1m 2 m 3 m 6-9m 
ENROLMENT: 
      
Eligibility screen 
(including smoking 
status and baseline 
AUDIT) 
X      
Informed consent  X      
Allocation  X     
Assigned trial ID and 
initial visit date 
 X     
INTERVENTIONS:       
The ProLife 
Programme 
      
Usual care       
ASSESSMENTS:       
Clinical review of TB 
treatment record 
X X    X 
HIV Status 
 X     
ART status (if HIV-
positive) 
 X   X X 
Smoking history 
X X     
Socio-demographic 
history 
 X     
Depression screen 
(CES-D10) 
 X   X X 
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Record sputum 
culture, smear or 
Gene Xpert result 
 X  X X X 
Smoking abstinence 
(self-report) 
    X X 
Smoking abstinence 
(Exhaled CO) 
    X X 
Repeat AUDIT 
    X X 
Modified ACTG 
    X X 
Economic evaluation 
 X   X X 
 378 
Data collection and management 379 
Data will be collected and recorded by field workers equipped with Android phones with a 380 
mobile data collection application installed. MI counselling and data collection will take place 381 
in a well-ventilated private area inside or outside the clinic (but within the grounds of the 382 
health facility), and MI sessions will be audio-recorded where consent has been obtained. 383 
Fieldworkers and LHWs will be provided with high particulate respirator masks to minimise 384 
the risk of infection. 385 
Fieldworkers will follow-up all participants in both arms at 3 and 6 months within a window 386 
period of 2 weeks before and 2 weeks after the ideal 3 and 6-month visit. Participants will 387 
receive SMS reminders 3 days before each planned visit. Participants will also be in a 388 
SRVLWLRQWRVHQG³SOHDVHFDOOPH´PHVVDJHVWRWKHGLVWULFWFRRUGLQDWRUVZKRZLOOWKHQFDOOWKH389 
participant to solve problems that may have arisen with the appointment. 390 
The electronic data captured will be stored on secured and password-protected storage servers 391 
and mobile phones which ensure data privacy through only allowing authorised research staff 392 
access to the data. The electronic data collection system used for the study requires an SMS 393 
gateway to VHQGDQGUHFHLYHPHVVDJHVWRWKHUHVHDUFKSDUWLFLSDQWV&RQVHQWLQJSDUWLFLSDQWV¶394 
phone numbers, participant IDs, and associated SMS messages will be stored on the SMS 395 
JDWHZD\¶VVHFXUHGDQGSDVVZRUGSURWHFWHGVHUYHU 396 
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Data quality will be ensured by providing fieldworkers with standard operating procedures 397 
(SOPs), training, and ongoing support on the importance of data quality, data collection, and 398 
data collection problem solving. Training will consist of a 4-day session before the 399 
commencement of the pilot and a one-day training session focusing on problems identified 400 
during the pilot preceded the trial. The data manager will continuously monitor the captured 401 
data for missing variables and inconsistencies in order to resolve any data problems.  402 
The data manager will export the data from the secured server, conceal the participants study 403 
arm allocation, and de-identify the data before sharing the data in STATA and R compatible 404 
formats.  The exported de-identified data will be stored in Dropbox, a secure cloud storage 405 
platform, for sharing with the lead trial statistician at the University of York for analysis.  406 
All research data and documents referring to the ProLife trial will be stored and maintained in 407 
a secured storage space at SMU for a minimum of 15 years from the end of the ProLife trial. 408 
Study materials will be destroyed 15 years after the study. 409 
 410 
Blinding and limitation of risk of bias 411 
This is a complex behavioural intervention and the team dynamics mean that all team 412 
members work very closely with one another. As such, LHWs and participants cannot be 413 
blinded to the intervention. The determination of the primary outcome will be done by the TB 414 
nurses who are blinded to the intervention status of the participants based on routinely 415 
collected data. Blinding of the field researchers collecting other questionnaire data (Appendix 416 
2) will not be possible. The statistician will be blinded to the intervention or control arm 417 
allocation of participants during the analysis stage.  418 
There is a potential of biased outcome reporting on self-reported tobacco smoking or alcohol 419 
consumption favouring the intervention arm. This will be minimised by training the 420 
fieldworkers in open communication and standardised data collection. Tobacco cessation will 421 
also be verified by exhaled CO monitoring. Given the use of the TB treatment record as a 422 
primary source of information pertaining to TB outcomes, there is a risk of non-differential 423 
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misclassification. However, this risk is equal in both the treatment and control arms and 424 
therefore the decision has been taken that the TB treatment record can be used as a primary 425 
data source (i.e. bias would be towards the null). 426 
 427 
Sample size 428 
The sample size has been set at 696 participants (348 participants per arm). This sample size 429 
is sufficient to detect a 10% difference in TB treatment success rates (0.86 vs. 0.76) in the 430 
ProLife group vs. the control group with 80% power, a significance level of 0.05 and 25% 431 
attrition. The sample size per clinic ranged from 14 to 74 participants per clinic with a median 432 
of 24. The assumed success rates in the control group are based on actual success rates in TB 433 
patients in the studied provinces. 434 
 435 
Statistical analysis 436 
We will summarise baseline data descriptively by trial arm, however, we will not undertake 437 
statistical comparisons. For continuous measures, we will report means and standard 438 
deviations (SD), and for skewed data we will also provide medians and inter-quartile ranges.  439 
For categorical data, we will report counts and percentages. For the primary outcome, we will 440 
conduct analysis on an intention-to-treat basis.  We will use binary logistic regression to 441 
compare the main outcome between the intervention and the usual care arm.  442 
We will carry out similar analyses for the secondary outcomes with appropriate regression 443 
techniques; logistic regression for categorical outcomes and linear regression for continuous 444 
outcomes. We will also adjust for baseline characteristics and other covariates (HIV-status, 445 
sex, alcohol vs. tobacco vs. both, district) if these differ between trial arms at baseline.  446 
In case of missing data, we will employ a number of methods including multiple imputations 447 
to assess the sensitivity of the results. We will conduct subgroup analyses to determine 448 
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whether TB treatment outcomes differ between subgroups, as follows: HIV-positive versus 449 
HIV-negative participants; participants with an alcohol problem only versus smokers only 450 
versus participants who are conjoint smokers and drinkers; and participants who were 451 
GeneXpert positive versus participants who were GeneXpert negative at baseline. 452 
We will follow the CONSORT statement guidelines in reporting. We will use the statistical 453 
packages STATA and R to carry out the analyses and a P-value < 0.05 will be considered as 454 
statistically significant.  The statistical analysis pertaining to cost-effectiveness will be 455 
described in the section detailing the planned economic evaluation. 456 
 457 
Monitoring 458 
Each centre will be responsible for its own data entry and local trial management. Monitoring 459 
and site training will be carried out at each site within specified intervals. The project 460 
manager will visit each district every third month with the counselling supervisor. The district 461 
coordinators will visit each clinic bi-weekly and the site leads and data manager will visit the 462 
sites when required.  463 
 464 
The monitoring will adhere to the principles of Good Clinical Practice and will follow an 465 
agreed monitoring plan. During their bi-weekly visits, the district coordinators will be guided 466 
by a checklist to confirm adherence to protocol, review eligibility verification and consent 467 
procedures, and provide additional training as needed. Any adverse events will be formally 468 
recorded and reported where appropriate. 469 
 470 
The mobile data collection tool was improved based on findings from the pilot phase and 471 
feedback from the field staff capturing the data. Validation was added to the mobile 472 
questionnaires to ensure that all questions should be answered, participants only answer 473 
question relevant to them, and that no unusual values (range checks) are entered. 474 
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Coordinators can use the mobile data collection tool on their phones to monitor incomplete 475 
data activities, outstanding and upcoming appointments with participants, and basic project 476 
performance indicators per clinic. 477 
 478 
The data captured during the interviews with the participants are only captured on the 479 
electronic mobile data collection tool and can therefore not be verified by the site 480 
coordinators. However, the district coordinators will require access to all (enrolled TB) 481 
patient medical records including, but not limited to, laboratory test results and prescriptions. 482 
They will do spot checks by comparing the captured data with the medical records and look 483 
for missed outcomes reporting; verify completeness, consistency and accuracy of data being 484 
entered on CRFs. The site leads (or delegated personnel) should work with the district 485 
coordinators to ensure that any problems detected are resolved. 486 
 487 
The data will also be checked by the data manager for missing or unusual values (range 488 
checks) and checked for consistency within participants over time. If any such problems are 489 
identified, the individual centres will be contacted and asked to verify or correct the entry.  490 
Indicators related to enrolment, premature withdrawal, motivational interviewing completion, 491 
CRF completion, and SMS delivery, will be analysed and included in monthly reports.   492 
 493 
As the ProLife programme is a low risk intervention, the decision was taken not to appoint an 494 
external data monitoring committee.  495 
 496 
Training and Intervention Fidelity Monitoring 497 
18 LHWs, 3 district coordinators and 1 person who will be focusing on counselling 498 
supervision underwent MI training over 5 days, which covered: basic knowledge of TB, 499 
treatment adherence, tobacco and alcohol use; overview of the overall spirit of MI and 500 
communication style; core interviewing skills; evoking change talk, hope and confidence; 501 
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GHYHORSLQJDFKDQJHSODQDQGVWUHQJWKHQLQJFRPPLWPHQW7KH/+:V¶NQRZOHGJHLQWHUPVRI502 
TB, alcohol use, tobacco smoking, TB and ART treatment adherence, and motivational 503 
interviewing was assessed before and after the training.  504 
To ensure that all the essential steps, techniques and skills of an MI session are covered 505 
during each session, the LHWs will be provided with a checklist to use during each session 506 
(Appendix 3). At the end of each session, they will also complete a post-session semi-507 
structured form onto which they will indicate the extent to which they implemented each 508 
element of MI, as well as their general qualitative impressions of that particular session. 509 
During the trial, the LHWs will receive regular supervisory support from the district and 510 
national study coordinators. In addition, an appointed supervisor with proficiency in MI will 511 
be providing monthly counselling supervision to the LHWs in each site, by travelling to each 512 
of the 3 sites and then providing support to the LHWs in a group, followed by individualised 513 
support to each LHW separately. All lay counsellors completed grade 12 and have at least 1 514 
year of prior counselling experience in TB and/or HIV.  515 
In order to assess the fLGHOLW\RIWKHFRXQVHOORUV¶GHOLYHU\RIPRWLYDWLRQDOLQWHUYLHZLQJGXULQJ516 
the trial, the validated Motivational Interviewing Treatment Integrity Coding Manual 4.2.1 517 
(MITI) tool will be used [43]:HZLOOWDSHUHFRUGHDFK/+:¶VFRXQVHOOLQJVHVVLRQVDQGWKHQ518 
UDQGRPO\VHOHFWRIHDFKFRXQVHOORU¶VSDWLHQWVDQGWKHQXVHWKHUHFRUGLQJVRIDOO3 sessions 519 
with those patients for the MITI task. Those selected recordings will be transcribed and 520 
translated into English. 2 independent raters who are Setswana/Sesotho speakers will listen to 521 
the recordings and code a randomly selected 20-minute portion of the written transcript. In 522 
the case of shorter counselling sessions, the entire recording will be assessed. The coding will 523 
entail PDNLQJµ*OREDO5DWLQJV¶RQ dimensions: Cultivating change talk, Softening sustain 524 
WDON3DUWQHUVKLSDQG(PSDWK\DQGµ%HKDYLRXU&RXQWV¶ZLWKUHVSHFWWRWKHLWHPVJLYLQJ525 
information, persuade, persuade with permission, question, simple reflection, complex 526 
reflection, affirm, seeking collaboration, emphasizing autonomy and confront). A score will 527 
be assigned to each of these items and the scores compared against the competency and 528 
proficiency thresholds that are specified in the MITI manual.  529 
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 530 
Economic evaluation 531 
The economic evaluation will be a within-trial incremental cost-effectiveness analysis of the 532 
ProLife package over and above usual care conducted alongside the RCT. In each arm of the 533 
trial, we will estimate the costs of delivering the intervention to participants. Costs consist of 534 
the delivery of ProLife intervention (staff costs, overheads and consumables) in the 535 
intervention arm, and the costs of behavioural support and support (staff time, overheads and 536 
consumables) in the control arm. Costs will be calculated based on the length of time of 537 
contacts and the unit cost of the health care worker delivering the intervention. These costs 538 
should demonstrate some within patient variability as cost will be partly dependent upon the 539 
length of the recorded appointments.   540 
 541 
We will also record contacts with health services for TB by patients in each trial arm, using 542 
the questionnaires adapted from those used in a previous trial of TB [44]. Applying unit costs 543 
of health care to quantities recorded in the service use questionnaire will produce a health 544 
care cost profile for each patient at baseline, three and six-month follow up. Health care cost 545 
profiles based on TB contacts can then be used to investigate differences in total costs 546 
between the treatment and control groups. The base case analysis will use health care costs as 547 
the study perspective. This is justified by presenting the cost implications of delivering the 548 
3UR/LIHLQWHUYHQWLRQIURPDKHDOWKFDUHGHFLVLRQPDNHU¶VSHUVSHFWLYH+RZHYer, we will also 549 
record paUWLFLSDQWV¶ travel costs associated with making the journey to the intervention site. 550 
This will estimate the wider societal cost to patients associated with receiving treatment.   551 
 552 
We will estimate the cost per additional successful TB outcome by computing an incremental 553 
cost effectiveness ratio (ICER) combining treatment and wider health care costs with outcome 554 
data from the trial. The analysis will also use measures of health utility. We have registered at 555 
the EuroQol website to use the country specific version of EQ-5D-3L for South Africa to 556 
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measure health related quality of life at baseline, 3 and 6 month follow up.  We will use EQ-557 
5D-3L to estimate changes in quality adjusted life years (QALY) using the area under the 558 
curve by using the utility score at each time point to create a profile [45]. A cost utility 559 
analysis is then performed by combining incremental health outcomes using QALYs with the 560 
incremental cost. The cost utility analysis will estimate the cost per QALY that estimates the 561 
value for money afforded by administering the ProLife intervention over and above usual 562 
care. We will plot incremental cost against incremental outcome using a cost-effectiveness 563 
plane. We will also conduct sensitivity analyses to assess the robustness of the ICER, and use 564 
bootstrapping techniques to calculate cost-effectiveness acceptability curves.  Supporting 565 
analysis will also present the costs to patients incurred by making visits to both trial arms to 566 
present the wider cost burden.  However, these costs will not be included in the base case 567 
scenario as the objective is to present the value for money from the perspective of the 568 
purchaser or commissioner. 569 
 570 
Discussion 571 
Ending the TB epidemic is one of the Sustainable Development Goals (SDG) established by 572 
the United Nations. WHO calls for a 90% reduction in TB incidence by 2030 compared to 573 
2015 and has highlighted the need for intensified research and innovation. The WHO has 574 
recently published guidance advocating the use of digital technologies, specifically mobile 575 
text messaging campaigns, in the treatment of TB as a means of improving the provision of 576 
patient-centred care and supporting medication adherence [46]. This publication highlights 577 
advances in mobile technologies and network coverage as opportunities to more effectively 578 
support patients during what can be a long period of treatment. This study is well-aligned 579 
with this guidance and, to our knowledge, this is the first trial looking at a complex 580 
behavioural intervention aiming to use MI techniques, alongside SMS, to modify a range of 581 
harmful lifestyle factors with the aim of improving TB treatment outcomes.  582 
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Work already undertaken in the formative phase suggests that the ProLife intervention is 583 
feasible and acceptable to patients. However, we anticipate some potential procedural 584 
challenges throughout the trial as we recognise that patients with TB may feel unwell and 585 
have taken steps to ensure that the MI and data collection are as brief and comfortable for 586 
patients as possible. The district coordinators will call participants to follow-up with those 587 
who missed appointments.  588 
Implementing complex interventions in the real world can pose logistical challenges and 589 
careful process evaluation will be required to fully understand the challenges that may be 590 
presented. However, there is evidence to suggest that using MI techniques can be cost-591 
effective when implemented in health care settings and the ProLife programme could 592 
represent a scalable and feasible approach to improving the care of patients with TB globally. 593 
Its scalability is particularly relevant in South Africa as the government plans to formally 594 
introduce community health workers as part of its health workforce.   595 
 596 
Trial status 597 
Protocol Version 1.2, 5 January 2018. Recruitment ongoing; piloting started at 30 clinics: 7 598 
May 2018 and was completed by 31 August. The actual trial enrolment started on 13 599 
November 2018. We expect to enrol the target sample size by May 2019 and plan to continue 600 
with follow-up until December 2019.  The trial was piloted internally from May 2018 until 601 
the end of August 2018 and piloting results will be reported at a later stage, together with the 602 
trial results. 603 
 604 
List of abbreviations 605 
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ACTG   AIDS Clinical Trials Group 606 
ART   Anti-retroviral therapy 607 
AUDIT   Alcohol Use Disorders Identification Test 608 
CO   Carbon monoxide 609 
CRF    Case Report Form 610 
EPTB   Extra-pulmonary TB 611 
HIV   Human immunodeficiency virus 612 
LHW   Lay health worker 613 
MI   Motivational interviewing 614 
PTB   Pulmonary TB 615 
SMS    Short Message Service 616 
SADHS  South Africa Demographic and Health Survey 617 
TB   Tuberculosis 618 
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Table 1: Definitions for TB treatment outcomes according to the South African Department of 679 
Health National Tuberculosis Management Guidelines. 680 
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Treatment 
outcome 
Definition 
Cure Patient in whom baseline smear or culture was positive at beginning of 
treatment AND is smear/culture negative in the last month of treatment and 
on at least 1 previous occasion at least 30 days prior 
According to local protocol, a patient who is diagnosed using Gene Xpert 
DQGLVVSXWXPQHJDWLYHIRU7%DWDQGZHHNVLVFRQVLGHUHG³&XUHG´ 
Treatment 
completed 
Patient whose baseline smear or culture was positive at the beginning and 
has completed treatment but does not have a negative smear/ culture in 
the last month of treatment and on at least 1 previous occasion more than 30 
days prior. Patients diagnosed with PTB whose baseline smear (or 
culture) result was negative and who started treatment based on 
clinical and radiological findings who have shown clinical improvement 
and completed the prescribed course of treatment. 
N.B. The smear examination may not have been done or the results may not 
be available at the end of treatment.  
Treatment 
failure 
Patient whose baseline smear or culture was positive and remains or 
becomes positive again at 5 months or later during treatment. 
Patients who were negative at baseline but were later found to be positive 
N.B. This definition excludes those patients who are diagnosed with RR-TB 
or MDR-TB during treatment.  
Died Patient who dies for any reason during the course of TB treatment.  
Treatment 
default 
Patient whose treatment was interrupted for 2 consecutive months or more 
during the treatment period.  
Transfer out Patient who was referred to a facility in another district to continue 
treatment and for whom the treatment outcome is not known.  
Acquired 
resistance 
Participants who are subsequently referred for MDR treatment. 
 681 
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Table 2: Summary of methods of data collection and analysis for primary and secondary 682 
outcomes 683 
Variable Method of data collection Method of data analysis 
Primary outcome: 
TB Treatment 
outcome as defined 
by WHO and the 
South Africa TB 
Management 
Guidelines (see 
Table 1) 
Ɣ CRF and TB Treatment Record 
Ɣ Treatment outcome as recorded by 
TB nurses in TB cards using the 
standard WHO definitions of cure, 
completions, failure, death, TB 
treatment interruption, drug 
resistance developed in course of 
treatment,  (confirmed for correctness 
by checking sputum culture/smear at 
baseline, at 5 and 6 months) 
Binary outcome: successful (cured 
of completed) versus not 
successful (died, failure, treatment 
interruption, drug resistant TB)  
All participants, excluding those 
transferred out. 
Secondary 
outcome: sputum 
conversion 
Ɣ Sputum culture/smear at baseline, 5 
and 6 months to determine cure rates 
for PTB patients who had a 
positive smear or culture at 
baseline 
Ɣ 6SXWXPFRQYHUVLRQDWҀPRQWKV 
Binary cured vs. not cured for the 
subgroups of participants who had 
a positive smear/culture at 
baseline. 
 
Binary conversion vs. not for the 
subgroups of participants who had 
a positive smear/culture at 
baseline. 
 
Secondary 
outcome: Change 
in smoking 
behaviour 
Ɣ CRF ± 4XHVWLRQVDVSHU5XVVHOO¶V
Standard ± baseline smoking 
behaviours and then at 3 and 6 
months 
Ɣ Exhaled carbon monoxide reading at 
3 months and 6 months 
Binary outcome validated 6 and 3 
months sustained smoking 
cessation for the subgroup of 
participants who were smoking at 
baseline. 
Secondary 
outcome: 
Percentage 
reduction in 
Ɣ AUDIT score at baseline and at 3 and 
6 months 
Change in AUDIT score 
(continuous) for subgroups of 
participants who were hazardous 
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harmful or 
hazardous drinking 
(change in AUDIT 
score) 
or harmful drinkers at baseline 
Secondary 
outcome:  HIV and 
TB medication 
adherence 
Ɣ CRF ± Questions modified from 
ACTG 
Binary outcome (% adherent 
vs. non-adherent) 
Secondary 
outcome: 
Proportion of HIV-
positive 
participants on 
ART 
Ɣ HIV status at baseline 
Ɣ ART status at baseline, 3 months and 
6 months 
Binary on ART vs. not on 
ART for the subgroup of HIV-
positive participants, taking 
into account baseline % on 
ART. 
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SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents* 
Section/item Item 
No 
Description Addressed on 
page number 
Administrative information 
 
Title 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym 1 
Trial registration 2a Trial identifier and registry name. If not yet registered, name of intended registry 3 
2b All items from the World Health Organization Trial Registration Data Set 1,2,3,6,8,9,10,17, 
18,25,26,27 
Protocol version 3 Date and version identifier 24 
Funding 4 Sources and types of financial, material, and other support 26 
Roles and 
responsibilities 
5a Names, affiliations, and roles of protocol contributors 1,27 
5b Name and contact information for the trial sponsor 27 
 5c Role of study sponsor and funders, if any, in study design; collection, management, analysis, and 
interpretation of data; writing of the report; and the decision to submit the report for publication, including 
whether they will have ultimate authority over any of these activities 
 
27 
 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint 
adjudication committee, data management team, and other individuals or groups overseeing the trial, if 
applicable (see Item 21a for data monitoring committee) 
 
 
 
16,17,19,20 
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 2 
Introduction 
   
Background and 
rationale 
6a Description of research question and justification for undertaking the trial, including summary of relevant 
studies (published and unpublished) examining benefits and harms for each intervention 
4,5 
 6b Explanation for choice of comparators 8 
Objectives 7 Specific objectives or hypotheses 6 
Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), 
allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 
 
6 
Methods: Participants, interventions, and outcomes  
Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 
be collected. Reference to where list of study sites can be obtained 
6 
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 
individuals who will perform the interventions (eg, surgeons, psychotherapists) 
8,9 
Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be 
administered 
7,8 
11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose 
change in response to harms, participant request, or improving/worsening disease) 
7,8,9 
11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence 
(eg, drug tablet return, laboratory tests) 
7,8,9 
11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 8 
Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood 
pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, 
median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen 
efficacy and harm outcomes is strongly recommended 
 
12,13,14 
Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for 
participants. A schematic diagram is highly recommended (see Figures 1 and 2) 
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 3 
Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including 
clinical and statistical assumptions supporting any sample size calculations 
18 
Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size 9,10 
Methods: Assignment of interventions (for controlled trials) 
 
Allocation:    
Sequence 
generation 
16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any 
factors for stratification. To reduce predictability of a random sequence, details of any planned restriction 
(eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants 
or assign interventions 
10 
Allocation 
concealment 
mechanism 
16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, 
opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned 
10 
Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to 
interventions 
10 
Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome 
assessors, data analysts), and how 
17,18 
 17b ,IEOLQGHGFLUFXPVWDQFHVXQGHUZKLFKXQEOLQGLQJLVSHUPLVVLEOHDQGSURFHGXUHIRUUHYHDOLQJDSDUWLFLSDQW¶V
allocated intervention during the trial 
17,18 
Methods: Data collection, management, and analysis 
 
Data collection 
methods 
18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related 
processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of 
study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. 
Reference to where data collection forms can be found, if not in the protocol 
16,17 
 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be 
collected for participants who discontinue or deviate from intervention protocols 
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 4 
Data management 19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality 
(eg, double data entry; range checks for data values). Reference to where details of data management 
procedures can be found, if not in the protocol 
16,17 
Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the 
statistical analysis plan can be found, if not in the protocol 
18,19 
 20b Methods for any additional analyses (eg, subgroup and adjusted analyses) 18,19 
 20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any 
statistical methods to handle missing data (eg, multiple imputation) 
 
18,19 
Methods: Monitoring 
 
Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of 
whether it is independent from the sponsor and competing interests; and reference to where further details 
about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not 
needed 
20 
 21b Description of any interim analyses and stopping guidelines, including who will have access to these interim 
results and make the final decision to terminate the trial 
19,20 
Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse 
events and other unintended effects of trial interventions or trial conduct 
19,20 
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent 
from investigators and the sponsor 
19,20 
Ethics and dissemination  
Research ethics 
approval 
24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval 26 
Protocol 
amendments 
25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, 
analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, 
regulators) 
26 
14 
15 
16 
17 
18 
19 
20 
21 
22 
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 5 
Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and 
how (see Item 32) 
10,11 
 26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary 
studies, if applicable 
NA 
Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared, and maintained 
in order to protect confidentiality before, during, and after the trial 
10,11,16,17 
Declaration of 
interests 
28 Financial and other competing interests for principal investigators for the overall trial and each study site 26 
Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that 
limit such access for investigators 
26 
Ancillary and post-
trial care 
30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial 
participation 
10,11 
Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, 
the public, and other relevant groups (eg, via publication, reporting in results databases, or other data 
sharing arrangements), including any publication restrictions 
26 
 31b Authorship eligibility guidelines and any intended use of professional writers NA 
 31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code NA 
Appendices 
   
Informed consent 
materials 
32 Model consent form and other related documentation given to participants and authorised surrogates Appendices 1 and 
2 
Biological 
specimens 
33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular 
analysis in the current trial and for future use in ancillary studies, if applicable 
NA 
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. 
Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons 
³Attribution-NonCommercial-NoDerivs 3.0 Unported´OLFHQVH. 
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